- Home
- UPB vs KBDC Comparison
UPB vs KBDC Comparison
Compare UPB & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPB
- KBDC
- Stock Information
- Founded
- UPB 2021
- KBDC 2021
- Country
- UPB United States
- KBDC United States
- Employees
- UPB N/A
- KBDC N/A
- Industry
- UPB
- KBDC
- Sector
- UPB
- KBDC
- Exchange
- UPB NYSE
- KBDC Nasdaq
- Market Cap
- UPB 1.1B
- KBDC 1.2B
- IPO Year
- UPB 2024
- KBDC N/A
- Fundamental
- Price
- UPB $16.21
- KBDC $16.67
- Analyst Decision
- UPB Strong Buy
- KBDC Buy
- Analyst Count
- UPB 4
- KBDC 5
- Target Price
- UPB $56.50
- KBDC $17.30
- AVG Volume (30 Days)
- UPB 462.3K
- KBDC 93.9K
- Earning Date
- UPB 02-14-2025
- KBDC 02-15-2025
- Dividend Yield
- UPB N/A
- KBDC 3.01%
- EPS Growth
- UPB N/A
- KBDC N/A
- EPS
- UPB N/A
- KBDC N/A
- Revenue
- UPB $2,207,000.00
- KBDC N/A
- Revenue This Year
- UPB N/A
- KBDC $172.54
- Revenue Next Year
- UPB N/A
- KBDC $14.28
- P/E Ratio
- UPB N/A
- KBDC N/A
- Revenue Growth
- UPB 82.10
- KBDC N/A
- 52 Week Low
- UPB $14.97
- KBDC $15.69
- 52 Week High
- UPB $29.46
- KBDC $17.22
- Technical
- Relative Strength Index (RSI)
- UPB N/A
- KBDC N/A
- Support Level
- UPB N/A
- KBDC N/A
- Resistance Level
- UPB N/A
- KBDC N/A
- Average True Range (ATR)
- UPB 0.00
- KBDC 0.00
- MACD
- UPB 0.00
- KBDC 0.00
- Stochastic Oscillator
- UPB 0.00
- KBDC 0.00
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.